This report provides a comprehensive analysis of the global antisense oligonucleotide (ASO)-based drug market, forecasting significant growth from 2025 through 2032. It examines the industry's trajectory by exploring key segments such as injection types and therapeutic applications, including neuromuscular diseases and hATTR. The study evaluates regional dynamics across the Americas, APAC, and Europe while profiling major industry players like Ionis Pharmaceuticals and Biogen. Ultimately, the research highlights emerging opportunities, competitive strategies, and the technological drivers shaping this evolving nucleic acid drug landscape.

Executive Overview

Global Market Projections

The global ASO-based Drug market size is predicted to grow from US$ 4553 million in 2025 to US$ 14190 million in 2032; it is expected to grow at a CAGR of 18.0% from 2026 to 2032.

Regional Market Projections

• United States: The market for ASO-based Drug is estimated to increase from 2025 through 2032, growing at a steady compound annual growth rate.
• China: The market for ASO-based Drug is estimated to increase from 2025 through 2032, growing at a steady compound annual growth rate.
• Europe: The market for ASO-based Drug is estimated to increase from 2025 through 2032, growing at a steady compound annual growth rate.

Product Definition & Technology

Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases.

Report Scope & Methodology

LPI (LP Information)' newest research report, the “ASO-based Drug Industry Forecast” looks at past sales and reviews total world ASO-based Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected ASO-based Drug sales for 2026 through 2032. With ASO-based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ASO-based Drug industry.

This Insight Report provides a comprehensive analysis of the global ASO-based Drug landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyses the strategies of leading global companies with a focus on ASO-based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global ASO-based Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ASO-based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ASO-based Drug. The report presents a comprehensive overview, market shares, and growth opportunities of ASO-based Drug market by product type, application, key players and key regions and countries.

Market Segmentation

By Type

• Intrathecal Injection
• Intravenous Injections
• Other

By Application

• Neuromuscular Diseases
• hATTR
• Other

By Geography

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, and market penetration:

• Ionis Pharmaceuticals
• Biogen
• Sobi
• Nippon Shinyaku
• Jazz Pharmaceuticals

Market Share

In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global ASO-based Drug Market Size (2021-2032)

    • 2.1.2 ASO-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for ASO-based Drug by Country/Region (2021, 2025 & 2032)

  • 2.2 ASO-based Drug Segment by Type

    • 2.2.1 Intrathecal Injection

    • 2.2.2 Intravenous Injections

    • 2.2.3 Other

    • 2.2.4 ASO-based Drug Market Size by Type

      • 2.2.4.1 ASO-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global ASO-based Drug Market Size Market Share by Type (2021-2026)

  • 2.3 ASO-based Drug Segment by Application

    • 2.3.1 Neuromuscular Diseases

    • 2.3.2 hATTR

    • 2.3.3 Other

    • 2.3.4 ASO-based Drug Market Size by Application

      • 2.3.4.1 ASO-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global ASO-based Drug Market Size Market Share by Application (2021-2026)

• 3 ASO-based Drug Market Size by Player

  • 3.1 ASO-based Drug Market Size Market Share by Player

    • 3.1.1 Global ASO-based Drug Revenue by Player (2021-2026)

    • 3.1.2 Global ASO-based Drug Revenue Market Share by Player (2021-2026)

  • 3.2 Global ASO-based Drug Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 ASO-based Drug by Region

  • 4.1 ASO-based Drug Market Size by Region (2021-2026)

  • 4.2 Global ASO-based Drug Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas ASO-based Drug Market Size Growth (2021-2026)

  • 4.4 APAC ASO-based Drug Market Size Growth (2021-2026)

  • 4.5 Europe ASO-based Drug Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa ASO-based Drug Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas ASO-based Drug Market Size by Country (2021-2026)

  • 5.2 Americas ASO-based Drug Market Size by Type (2021-2026)

  • 5.3 Americas ASO-based Drug Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC ASO-based Drug Market Size by Region (2021-2026)

  • 6.2 APAC ASO-based Drug Market Size by Type (2021-2026)

  • 6.3 APAC ASO-based Drug Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe ASO-based Drug Market Size by Country (2021-2026)

  • 7.2 Europe ASO-based Drug Market Size by Type (2021-2026)

  • 7.3 Europe ASO-based Drug Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa ASO-based Drug by Region (2021-2026)

  • 8.2 Middle East & Africa ASO-based Drug Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa ASO-based Drug Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global ASO-based Drug Market Forecast

  • 10.1 Global ASO-based Drug Forecast by Region (2027-2032)

    • 10.1.1 Global ASO-based Drug Forecast by Region (2027-2032)

    • 10.1.2 Americas ASO-based Drug Forecast

    • 10.1.3 APAC ASO-based Drug Forecast

    • 10.1.4 Europe ASO-based Drug Forecast

    • 10.1.5 Middle East & Africa ASO-based Drug Forecast

  • 10.2 Americas ASO-based Drug Forecast by Country (2027-2032)

    • 10.2.1 United States Market ASO-based Drug Forecast

    • 10.2.2 Canada Market ASO-based Drug Forecast

    • 10.2.3 Mexico Market ASO-based Drug Forecast

    • 10.2.4 Brazil Market ASO-based Drug Forecast

  • 10.3 APAC ASO-based Drug Forecast by Region (2027-2032)

    • 10.3.1 China ASO-based Drug Market Forecast

    • 10.3.2 Japan Market ASO-based Drug Forecast

    • 10.3.3 Korea Market ASO-based Drug Forecast

    • 10.3.4 Southeast Asia Market ASO-based Drug Forecast

    • 10.3.5 India Market ASO-based Drug Forecast

    • 10.3.6 Australia Market ASO-based Drug Forecast

  • 10.4 Europe ASO-based Drug Forecast by Country (2027-2032)

    • 10.4.1 Germany Market ASO-based Drug Forecast

    • 10.4.2 France Market ASO-based Drug Forecast

    • 10.4.3 UK Market ASO-based Drug Forecast

    • 10.4.4 Italy Market ASO-based Drug Forecast

    • 10.4.5 Russia Market ASO-based Drug Forecast

  • 10.5 Middle East & Africa ASO-based Drug Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market ASO-based Drug Forecast

    • 10.5.2 South Africa Market ASO-based Drug Forecast

    • 10.5.3 Israel Market ASO-based Drug Forecast

    • 10.5.4 Turkey Market ASO-based Drug Forecast

  • 10.6 Global ASO-based Drug Forecast by Type (2027-2032)

  • 10.7 Global ASO-based Drug Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market ASO-based Drug Forecast

• 11 Key Players Analysis

  • 11.1 Ionis Pharmaceuticals

    • 11.1.1 Ionis Pharmaceuticals Company Information

    • 11.1.2 Ionis Pharmaceuticals ASO-based Drug Product Offered

    • 11.1.3 Ionis Pharmaceuticals ASO-based Drug Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Ionis Pharmaceuticals Main Business Overview

    • 11.1.5 Ionis Pharmaceuticals Latest Developments

  • 11.2 Biogen

    • 11.2.1 Biogen Company Information

    • 11.2.2 Biogen ASO-based Drug Product Offered

    • 11.2.3 Biogen ASO-based Drug Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Biogen Main Business Overview

    • 11.2.5 Biogen Latest Developments

  • 11.3 Sobi

    • 11.3.1 Sobi Company Information

    • 11.3.2 Sobi ASO-based Drug Product Offered

    • 11.3.3 Sobi ASO-based Drug Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Sobi Main Business Overview

    • 11.3.5 Sobi Latest Developments

  • 11.4 Nippon Shinyaku

    • 11.4.1 Nippon Shinyaku Company Information

    • 11.4.2 Nippon Shinyaku ASO-based Drug Product Offered

    • 11.4.3 Nippon Shinyaku ASO-based Drug Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Nippon Shinyaku Main Business Overview

    • 11.4.5 Nippon Shinyaku Latest Developments

  • 11.5 Jazz Pharmaceuticals

    • 11.5.1 Jazz Pharmaceuticals Company Information

    • 11.5.2 Jazz Pharmaceuticals ASO-based Drug Product Offered

    • 11.5.3 Jazz Pharmaceuticals ASO-based Drug Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Jazz Pharmaceuticals Main Business Overview

    • 11.5.5 Jazz Pharmaceuticals Latest Developments

• 12 Research Findings and Conclusion